Introduction {#Sec1}
============

Appropriate antithrombotic treatment in patients with atrial fibrillation (AF), who undergo OAC (PCI) is still unresolved. Dual antiplatelet therapy (DAPT) appears to be mandatory after PCI to reduce the risk of myocardial infarction (MI) and stent thrombosis (ST) \[[@CR1]\], while long-term treatment with oral anticoagulation (OAC) is indicated in patients with AF to prevent stroke or systemic embolism \[[@CR2]\]. Accordingly, current guidelines recommend triple therapy (TT) with DAPT plus OAC for at least 1 month after PCI \[[@CR3], [@CR4]\]. TT, however, substantially increases the risk of bleeding \[[@CR5]\]. Favorable results were reported for a treatment strategy with dual therapy (DT) using single antiplatelet therapy plus vitamin K antagonists (VKAs) after PCI \[[@CR7]--[@CR10]\]. Novel oral anticoagulants (NOACs) are suitable alternatives to VKAs for stroke prevention in non-valvular AF and their use in clinical practice is increasing rapidly \[[@CR11]\], also driven by guideline recommendation as first-line preference \[[@CR12]\]. DT using NOACs and P2Y~12~ inhibitors may replace TT in AF patients with PCI, but so far, many questions are still open regarding this new antithrombotic strategy. First, it is unclear which medications are the best agents to combine. With several P2Y~12~ inhibitors and four NOAC agents, multiple potential drug combinations exist. Second, the optimal duration of DT and the dosage of NOAC is unclear. The recently published PIONEER AF-PCI trial \[[@CR13]\] and REDUAL-PCI trial \[[@CR14]\] as well as the ongoing ENTRUST-AF-PCI and the AUGUST studies aim to investigate the value of NOACs in combination with P2Y~12~ inhibitors. PIONEER AF and REDUAL-PCI showed that DT using NOAC significantly reduced bleeding compared to TT using VKA. Both trials, however, are underpowered for other clinical endpoints and thus clinical data in this area are of current interest. As the optimal antithrombotic treatment strategy for AF patients with PCI is still unresolved, the aim of this study was to assess safety and efficacy of 6 months DT with NOAC and P2Y~12~ inhibitor.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This retrospective analysis was performed in a single-center prospective cohort study aiming for consecutive enrolment of all AF patients with indication for PCI and OAC at the Heart Center Segeberger Kliniken, Bad Segeberg, Germany. The current analysis includes 216 consecutive AF patients who underwent PCI from July 2013 to May 2016. Clinical follow-up was performed at least 6 months after the procedure. It was conducted by hospital visit or phone contact. A clinical event committee reviewed patient medical records including clinical events and hospital admissions in case of any adverse event.

Interventional Procedure {#Sec4}
------------------------

The indications for PCI and procedures were performed in accordance with the current guidelines and included stable coronary artery disease (CAD) as well as acute coronary syndromes (ACS). Procedural techniques were left to the operator's discretion and generally did not differ from non AF patients. To provide a real-world case study, all clinical presentations and procedural entities were included, as long as NOACs were not contraindicated. All patients received a loading dose of 500 mg acetylsalicylic acid intravenously and 600 mg clopidogrel or 60 mg prasugrel orally. Unfractionated heparin was given intra-arterially during PCI at a dose of 5000--7000 U with a target ACT time of \> 250 s. Patients did not take NOAC on the day of the procedure.

All procedures were performed transfemorally and arterial closure devices were used in all patients (FemoSeal™, Terumo Europe NV). In addition, access site was supplied with a pressure bandage for 3 h after removal of the sheath as in-house standard after transfemoral access.

Endpoint Definition {#Sec5}
-------------------

Pre-specified efficacy endpoints of this study were cardiac death, MI, ST, and stroke as defined by the Academic Research Consortium (ARC) \[[@CR15]\]. Safety endpoint was the occurrence of bleeding events, defined by Bleeding Academic Consortium (BARC) \[[@CR16]\].

Antithrombotic Regimen {#Sec6}
----------------------

All patients had indication for OAC due to non-valvular AF with risk factors. After PCI, patients received reduced dosage NOAC plus a P2Y~12~ inhibitor for 6 months, followed by standard dosage of NOAC monotherapy. Most patients were already on NOAC at the time of the presentation and maintained the therapy, so the decision for a certain NOAC mainly depended on the referring physicians.

Statistical Analysis {#Sec7}
--------------------

All data were processed using Excel 2016 (Microsoft) and Prism 7.0 (GraphPad). The descriptive statistical characteristics for quantitative parameters are listed as mean ± standard deviation for normally distributed data and as median with interquartile range for non-normally distributed data. Event-free survival for groups was constructed using Kaplan--Meier method.

Compliance with Ethics Guidelines {#Sec8}
---------------------------------

All procedures were in accordance with ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed written consent for the procedure was obtained from all patients.

Results {#Sec9}
=======

A total of 220 patients with AF and need for OAC were consecutively treated with PCI from July 2013 until May 2016. Only four patients were lost to follow-up and excluded from final analysis. Detailed patients' baseline and clinical characteristics are summarized in Table [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Mean age of the study population was 74.8 ± 1.3 years, and 80.1% were males. The comorbidity index was high, with 30.1% of the patients being diabetics, 13.4% with previous MI, 10.2% with previous ischemic events, and 22.7% with impaired renal function (glomerular filtration rate \< 60 ml/min). The mean CHA~2~DS~2~-VASc score of our population was 4.4 ± 1.2 with a mean HAS-BLED score of 3.0 ± 0.2 representing a high-risk group for thromboembolic as well as bleeding events.Table 1Baseline characteristicsAge (years) mean ± SD74.8 ± 1.3Male, *n* (%)174 (80.1)BMI (kg/m^2^), mean ± SD28.4 ± 4.95Comorbidity and cardiac risk factors Diabetes mellitus, *n* (%)65 (30.1) Hypertension, *n* (%)201 (93.1) Dyslipidemia, *n* (%)112 (51.8) Current smoker, *n* (%)27 (12.5) Previous MI, *n* (%)29 (13.4) Previous CABG, *n* (%)24 (11.1) Previous cerebral ischemia, *n* (%)22 (10.2) Peripheral vessel disease, *n* (%)39 (18.1) Chronic renal failure (GFR \< 60), *n* (%)49 (22.7) Previous PCI, *n* (%)85 (39.4) Table 2Clinical characteristicsClinical presentation Stable angina, *n* (%)179 (82.9) Acute coronary artery disease, *n* (%)37 (17.1)  Unstable angina, *n* (%)21 (9.7)  NSTEMI, *n* (%)10 (4.6)  STEMI, *n* (%)6 (2.8)Left ventricular ejection fraction, mean ± SD52.3 ± 11.59Left ventricular ejection fraction ≤ 30%, *n* (%)19 (8.8)CHA~2~DS~2~-Vasc score, mean ± SD4.3 ± 1.24CHA~2~DS~2~-Vasc score, median (range)4 (2--8)Coronary artery disease 1 VD, *n* (%)58 (26.8) 2 VD, *n* (%)74 (34.3) 3 VD, *n* (%)84 (38.9)

Three-quarters of the patients had multivessel coronary disease; 37 patients (17.1%) presented with ACS. Stents were implanted in 93.5% in of the patients. On average, two stents were implanted with a mean total stent length of 35 mm; 89.8% of the stents were new-generation drug-eluting stents (DES). A drug-eluting balloon PCI was performed in 5.5% of the patients, 0.9% were treated with thrombus aspiration. Further procedural details are given in Table [3](#Tab3){ref-type="table"}.Table 3Procedural characteristicsTarget vessel, *n* (%) Left main coronary artery17 (6.2) Left anterior descending artery109 (40.1) Right coronary artery83 (30.5) Left circumflex artery53 (19.5) Bypass graft, *n* (%)10 (3.7)Number of target vessels, *n* (%) One target vessel168 (77.8) Two target vessels40 (18.5) Three target vessels8 (3.7)Stents per patient, mean ± SD2 ± 1Total stent length (mm), mean ± SD35.25 ± 25Drug-eluting stents, *n* (%)194 (89.8)Bare metal stents, *n* (%)8 (3.7)Drug-eluting balloon, *n* (%)12 (5.5)Other, *n* (%)2 (0.9)

Antithrombotic Regimen {#Sec10}
----------------------

After the procedure, patients were treated with DT using reduced dosage NOAC, i.e., rivaroxaban 15 mg once-daily in 182 patients (84.3%), dabigatran 110 mg twice-daily in 17 patients (7.9%), apixaban 2.5 mg twice-daily in 16 patients (7.4%), or edoxaban 30 mg once-daily in one patient (0.5%), starting the day after procedure in combination with either clopidogrel (*n* = 214; 99.1%) or prasugrel (*n* = 2; 0.9%). The duration of recommended DT was 6 months but was reduced to 4 weeks in two patients (0.9%) and extended up to one year in 14 patients (6.5%). The mean duration of recommended DT treatment was 6.3 ± 1.7 months (Fig. [1](#Fig1){ref-type="fig"}). DT was followed by a monotherapy of the respective NOAC using the regular dose as indicated for non-valvular AF.Fig. 1Study design and patient enrolment

Outcomes {#Sec11}
--------

Clinical follow-up was available in 216 patients (98.2%) with a mean follow-up duration of 18.7 months. Bleeding was more frequently reported on DT than on NOAC monotherapy. During a mean DT of 6.3 months, bleeding events occurred in 11.5% of patients, while within the following NOAC monotherapy (mean, 11.9 months) only 3.2% of the patients experienced bleeding.

Bleeding events occurred in 34 of the patients (Table [4](#Tab4){ref-type="table"}). Mild bleeding (BARC 1--2) was 6.5% on DT and 2.8% under NOAC monotherapy. Moderate and severe bleeding (BARC 3a--3c) was 4.6% on DT and 0.5% under NOAC monotherapy. There was only one fatal bleeding due to a hemorrhagic shock a few days after the index PCI while the patient was on DT, whereas no fatal bleeding happened during the following NOAC monotherapy. Two bleeding events (BARC 3a, 3c) occurred in patients who had changed recommended treatment and were on VKAs. The most common bleeding complications were recurrent epistaxis (*n* = 10) and access route related bleeding (*n* = 8). Further bleeding sites were gastrointestinal in six, intramuscular in two, trauma caused by collapse in two, intracerebral in one, and of unknown origin in four. Bleeding according to TIMI classification was detailed in Table [4](#Tab4){ref-type="table"} (major in seven (3.2%), minor in five (2.3%) and minimal in nine (4.2%)). Eighteen patients had changed the recommended treatment strategy mainly because of recurrent epistaxis, renal dysfunction, valve replacement, and left ventricular thrombus formation. Timing of all bleeding events is shown in Fig. [2](#Fig2){ref-type="fig"}.Table 4Bleeding events at follow-upBARC type, *n* (%) BARC 113 (6.0) BARC 27 (3.2) BARC 3a4 (1.8) BARC 3b6 (2.8) BARC 3c3 (1.4) BARC 40 BARC 5a0 BARC 5b1 (0.45)TIMI type, *n* (%) Major7 (3.2) Minor5 (3.2) Minimal9 (4.2) Bleeding requiring medical attention13 (6.0) Clinically significant bleeding25 (11.5) Fig. 2Timing of all bleeding events. Bleeding events in patients with dual therapy (DT), NOAC monotherapy, and interruption of recommended antithrombotic treatment at some point before the occurrence of bleeding event

Efficacy events occurred in 12 (5.6%) of the patients (Table [5](#Tab5){ref-type="table"}). All-cause mortality was 2.8% with a cardiac mortality of 1.4%. Non-cardiovascular deaths were due to sepsis (*n* = 2), cancer (*n* = 2), paralytic ileus (*n* = 1), and renal failure (*n* = 1). We observed two MIs (0.9%) and one definite ST (0.5%). Six strokes were reported (2.8%), all were ischemic. Only two of these occurred during DT period with reduced dose NOAC, whereas four patients suffered stroke during the following period of NOAC monotherapy in standard dose. Efficacy events occurred in 2.4% on DT (one cardiac death, one MI, one definite ST and two strokes), while 3.2% were seen on following NOAC monotherapy (two cardiac deaths, one MI, and four strokes; Fig. [3](#Fig3){ref-type="fig"}). As shown in Fig. [3](#Fig3){ref-type="fig"}, ischemic events were equally distributed throughout the whole observation period.Table 5Efficacy events at follow-upDeath, *n* (%)9 (4.2) Cardiac death3 (1.4) Vascular death0 (0) Non-cardiovascular death6 (2.8)Spontaneous MI, *n* (%)2 (0.9) Stent thrombosis, *n* (%) Definite1 (0.5) Probable0 (0) Possible0 (0)Stroke, *n* (%)6 (2.8) Ischemic6 (2.8) Hemorrhagic0 (0) Fig. 3Timing of all efficacy events. Efficacy events in patients with dual therapy (DT) and NOAC monotherapy at some point before the occurrence of efficacy event

Discussion {#Sec12}
==========

The principal finding of this study is that 6-month DT consisting of NOAC plus P2Y~12~ inhibitor is safe and effective in high-risk AF patients with PCI. Moreover, with the de-escalation from DT to NOAC monotherapy, the risk of bleeding is further reduced.

For patients with indication for long-term OAC and PCI, guidelines recommend TT for at least 1 month \[[@CR3], [@CR4]\]. TT, however, increases the risk of fatal and non-fatal bleeding \[[@CR5]\]. Despite recommendations for TT, real-world data reveal that discharge medication in most patients who had undergone PCI and require chronically anticoagulation consists of DAPT or DT using an OAC with single antiplatelet agent \[[@CR6]\]. Several studies compared DT with TT. The WOEST trial randomized 573 patients with need for long-term OAC to DT (warfarin plus clopidogrel) or TT (warfarin plus clopidogrel plus acetylsalicylic acid in an open-label design. The group receiving DT had significantly lower rates of any bleeding and even less ischemic events within 1 year after PCI than the group receiving TT \[[@CR7]\].

Despite the widespread use of NOACs, their role in AF patients undergoing PCI is widely unknown. It is unclear which dose of a NOAC should be used in combination with antiplatelet agents and which duration of DT is optimal. Currently it is also unknown whether antiplatelet therapy with NOAC is superior to antiplatelet therapy combined with VKA. Because addition of any type of single or dual antiplatelet therapy to VKA or NOAC anticoagulation significantly increases the risk of major bleeding, the European guidelines recommend maintaining the INR within 2--2.5 during triple or DT with VKA and reducing doses of NOAC \[[@CR3]\]. To date, only two trials have randomly assigned patients requiring chronic anticoagulation and undergoing PCI to TT versus DT with NOAC. Published in 2016, the PIONEER AF-PCI trial included 2214 AF patients who had just undergone PCI to compare the safety of two rivaroxaban treatment strategies (15 mg rivaroxaban plus a P2Y~12~ inhibitor or 2.5 mg rivaroxaban twice daily plus DAPT) versus a TT using VKA. At 12 months, the primary outcome of clinically significant bleeding was lower in the rivaroxaban group than in the VKA group and lowest in the 15 mg rivaroxaban group \[[@CR13]\]. In the recently published REDUAL-PCI trial, 2752 patients were either treated with DT or with TT. The TT group received VKA plus a P2Y~12~ inhibitor and acetylsalicylic acid, while the DT group received dabigatran (110 mg or 150 mg twice daily) plus a P2Y~12~ inhibitor \[[@CR14]\]. These results reassured the findings of PIONEER-AF-PCI showing significantly lower rates of clinically relevant bleeding in the DT groups receiving reduced-dosage NOAC than in the group receiving TT. While these trials have been designed and powered for the primary safety endpoint of bleeding events, the secondary efficacy endpoint of cardiovascular events has not been adequately powered, even when enrolling several thousands of patients. This illuminates the difficulty in conducting a randomized controlled trial with its need for even larger cohorts to address this question. Adding more data supporting the efficacy of DT should therefore be of current interest and clinical importance.

We mainly utilized the DT regime of PIONEER-AF but shortened DT from 12 to 6 months. This was justified by a higher bleeding risk of DT than monotherapy and the declining risk of stent thrombosis within the first months after PCI. Furthermore, our patient cohort was mainly representative of stable CAD and high bleeding risk, so that 6 months of DT was an appropriate method.

With a mean age of nearly 75 years, a CHA~2~DS~2~-Vasc score of 4, and a HAS-BLED score of 3, our population has a higher patient-related risk for ischemic and bleeding events than patients in PIONEER-AF-PCI and in REDUAL-PCI. Moreover, the number and total length of stents indicate a high procedure-related risk. Nevertheless, the observed event rates are lower or at least similar to the two large RCTs. Clinically significant bleeding of 11.5% in our cohort is slightly lower than 16.8% in the respective DT arm in PIONEER-AF PCI (13) or 15.4% in the DT arm with 110 mg dabigatran in RE-DUAL PCI (14). Of note, the applied bleeding definitions differ slightly between both large trials, but may allow a cautious estimation. With respect to the efficacy endpoint events, we found a cardiovascular death rate of 1.4%, which is lower than 2.4% in the respective DT arm of PIONEER-AF PCI and 5.6% in the DT arm with 110 mg dabigatran in RE-DUAL PCI. The incidence of 0.9% myocardial infarction in our patients is lower than 3.0% in PIONEER-A PCI and 4.5% in RE-DUAL PCI of the respective treatment arms. The same applies with respect to definite and probable stent thromboses of 0.5% compared to 0.8% in PIONEER-AF PCI and 1.5% in RE-DUAL PCI. Of note, the triple therapy arms with double antiplatelet agent in the large randomized trials demonstrated a rate of stent thrombosis in the range of 0.7 to 0.9%, which is not lower than the rate in our patients only receiving one antiplatelet agent. However, we found a somewhat higher rate of stroke with 2.8% compared to 1.3% in PIONEER-A PCI and 1.7% in RE-DUAL PCI of the respective treatment arms with DT. Of these six patients in our cohort with a stroke event, only two strokes (0.9%) where noted during the phase of DT with a reduced NOAC dosage, whereas the majority of strokes where seen in a phase where NOAC was already administered in the approved dosage.

As we had a 98% follow-up rate and always full access to the patients' charts, it is very unlikely that our analysis suffers from serious underreporting of events. Our results rather support the contention that we should further reduce the aggressiveness of our antithrombotic therapy in elderly high-risk post PCI patients with AF. One might argue that 12 months of DT would have been more beneficial than 6 months of DT in our patients. DT, however, did not prevent the progression of thrombotic complications between month 6 and 12 in the RCTs, while our strategy halted bleeding in the same period after PCI.

Study Limitations {#Sec13}
-----------------

This study has all the limitations of a single-center observational study. The sample size of the study was small and no inference about comparative outcomes can be made due to lack of a control group. Secondly, different from the RCTs, our collective comprises mainly patients with stable CAD, which may compromise valid comparison to other published studies.

Conclusions {#Sec14}
===========

This single-center analysis suggests that 6 months of DT using a reduced dosage of NOAC plus P2Y~12~ inhibitor followed by standard dosage NOAC monotherapy is a safe and effective antithrombotic strategy for PCI patients with AF and need of OAC.
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